Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world.
Di Cosimo S, La Rocca E, Ljevar S, De Santis MC, Bini M, Cappelletti V, Valenti M, Baili P, de Braud FG, Folli S, Scaperrotta G, Volpi C, Vingiani A, Vernieri C, Verderio P, Miceli R, Pruneri G. Di Cosimo S, et al. Among authors: vingiani a. Front Mol Biosci. 2022 Sep 26;9:996434. doi: 10.3389/fmolb.2022.996434. eCollection 2022. Front Mol Biosci. 2022. PMID: 36225259 Free PMC article.
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E, Gelber RD, Regan MM, Colleoni M. Pruneri G, et al. Among authors: vingiani a. Breast Cancer Res Treat. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2. Breast Cancer Res Treat. 2016. PMID: 27372069 Free PMC article. Clinical Trial.
Tumor infiltrating lymphocytes in early breast cancer.
Pruneri G, Vingiani A, Denkert C. Pruneri G, et al. Among authors: vingiani a. Breast. 2018 Feb;37:207-214. doi: 10.1016/j.breast.2017.03.010. Epub 2017 Mar 28. Breast. 2018. PMID: 28363679 Review.
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.
Patten DK, Corleone G, Győrffy B, Perone Y, Slaven N, Barozzi I, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P, Pruneri G, Magnani L. Patten DK, et al. Among authors: vingiani a. Nat Med. 2018 Sep;24(9):1469-1480. doi: 10.1038/s41591-018-0091-x. Epub 2018 Jul 23. Nat Med. 2018. PMID: 30038216 Free PMC article.
100 results